Bioorthogonal chemistry provides a versatile strategy for programming nanomedicines beyond static carrier design. It enables post-synthetic installation of functional modules on nanoparticle surfaces, spatiotemporal control of payload activation and release, and higher-order functions arising from nanoparticle aggregation or nanoparticle–cell conjugation in diseased tissues. These capabilities allow nanomedicines to be activated more selectively in space and time and to generate functions that are difficult to achieve with conventional formulations. This review summarizes recent advances in multiscale bioorthogonal engineering for programmable nanomedicines, focusing on surface functionalization, molecular control of drug release, and interparticle or cell-associated assembly, and discusses challenges and future directions. Graphical abstract
Glucose acts as a fundamental energy substrate sustaining human physiological homeostasis, and aberrant blood glucose levels are tightly correlated with a spectrum of metabolic disorders, particularly diabetes mellitus, which has...
Two-dimensional (2D) materials have attracted significant attention owing to their distinctive physicochemical properties arising from their ultrathin planar architectures. While the term “2D materials” is traditionally associated with...
Atomically thin transition-metal dichalcogenides (TMDs) offer excellent electrostatic control for scaled transistors, but their integration into complementary metal–oxide–semiconductor (CMOS) technology requires careful control of...
Threshold-voltage (V t ) control without sacrificing the memory window remains a key challenge for energy-efficient ferroelectric field-effect transistor (FeFET)-based in-memory computing. Here, we introduce a novel fluorine surface...
Abstract Filter-free discrimination of visible (VIS) and near-infrared (NIR) light within a single photodetector pixel remains challenging because conventional photodiodes typically require optical filters or multiple detector elements....